
## Jane L Wolstenholme

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1193695/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Quality of life, healthcare use and costs in â€~at-risk' children after early antibiotic treatment versus placebo for influenza-like illness: within-trial descriptive economic analyses of the ARCHIE randomised controlled trial. BMJ Open, 2022, 12, e049373.	1.9	1
2	Estimating BMI distributions by age and sex for local authorities in England: a small area estimation study. BMJ Open, 2022, 12, e060892.	1.9	0
3	Survival, Dependency, and Health-Related Quality of Life in Patients With Ruptured Intracranial Aneurysm: 10-Year Follow-up of the United Kingdom Cohort of the International Subarachnoid Aneurysm Trial. Neurosurgery, 2021, 88, 252-260.	1.1	18
4	Quality of life in the FOXFIRE, SIRFLOX and FOXFIREâ€global randomised trials of selective internal radiotherapy for metastatic colorectal cancer. International Journal of Cancer, 2020, 147, 1078-1085.	5.1	11
5	PRIMEtime CE: a multistate life table model for estimating the cost-effectiveness of interventions affecting diet and physical activity. BMC Health Services Research, 2019, 19, 485.	2.2	17
6	Estimating the cost-effectiveness of salt reformulation and increasing access to leisure centres in England, with PRIMEtime CE model validation using the AdViSHE tool. BMC Health Services Research, 2019, 19, 489.	2.2	10
7	The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial. British Journal of Cancer, 2019, 121, 443-454.	6.4	20
8	Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study. Cancer Epidemiology, 2018, 52, 99-105.	1.9	8
9	Resource utilisation and costs in predementia and dementia: a systematic review protocol. BMJ Open, 2018, 8, e019060.	1.9	11
10	Supporting prostate cancer survivors in primary care: Findings from a pilot trial of a nurse-led psycho-educational intervention (PROSPECTIV). European Journal of Oncology Nursing, 2018, 32, 73-81.	2.1	17
11	Economic analysis of oral dexamethasone for symptom relief of sore throat: the UK TOAST study. BMJ Open, 2018, 8, e019184.	1.9	8
12	Preference-based measures to obtain health state utility values for use in economic evaluations with child-based populations: a review and UK-based focus group assessment of patient and parent choices. Quality of Life Research, 2018, 27, 1769-1780.	3.1	21
13	Measuring quality of life of people with predementia and dementia and their caregivers: a systematic review protocol. BMJ Open, 2018, 8, e019082.	1.9	17
14	Recruitment to the "Breast—Activity and Healthy Eating After Diagnosis―(B-AHEAD) Randomized Controlled Trial. Integrative Cancer Therapies, 2018, 17, 131-137.	2.0	9
15	Translational health economics: The key to accountable adoption of in vitro diagnostic technologies. Health Services Management Research, 2018, 31, 43-50.	1.7	7
16	Estimating comparable English healthcare costs for multiple diseases and unrelated future costs for use in health and public health economic modelling. PLoS ONE, 2018, 13, e0197257.	2.5	22
17	Early use of Antibiotics for at Risk CHildren with InfluEnza (ARCHIE): protocol for a double-blind, randomised, placebo-controlled trial. BMJ Open, 2018, 8, e021144.	1.9	3
18	Systematic literature review of methodologies and data sources of existing economic models across the full spectrum of Alzheimer's disease and dementia from apparently healthy through disease progression to end of life care: a systematic review protocol BMJ Open, 2018, 8, e020638.	1.9	8

JANE L WOLSTENHOLME

#	Article	IF	CITATIONS
19	Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT. Health Technology Assessment, 2018, 22, 1-96.	2.8	33
20	Effect of Oral Dexamethasone Without Immediate Antibiotics vs Placebo on Acute Sore Throat in Adults. JAMA - Journal of the American Medical Association, 2017, 317, 1535.	7.4	29
21	Process mining routinely collected electronic health records to define real-life clinical pathways during chemotherapy. International Journal of Medical Informatics, 2017, 103, 32-41.	3.3	69
22	Including Health Economic Analysis in Pilot Studies: Lessons Learned from a Cost-Utility Analysis within the PROSPECTIV Pilot Study. Global & Regional Health Technology Assessment, 2017, 4, grhta.5000269.	0.1	4
23	Estimating the variation in need for community-based social care by body mass index in England and associated cost: population-based cross-sectional study. BMC Public Health, 2017, 17, 667.	2.9	8
24	The Burden of Healthcare Costs Associated with Prostate Cancer in Ireland. Global & Regional Health Technology Assessment, 2017, 4, grhta.5000249.	0.1	1
25	Symptoms, unmet needs, psychological wellâ€being and health status in survivors of prostate cancer: implications for redesigning followâ€up. BJU International, 2016, 117, E10-9.	2.5	120
26	Choosing an epidemiological model structure for the economic evaluation of non-communicable disease public health interventions. Population Health Metrics, 2016, 14, 17.	2.7	67
27	Oral corticosteroid use for clinical and cost-effective symptom relief of sore throat: study protocol for a randomized controlled trial. Trials, 2014, 15, 365.	1.6	4
28	PROSPECTIV—a pilot trial of a nurse-led psychoeducational intervention delivered in primary care to prostate cancer survivors: study protocol for a randomised controlled trial: TableÂ1. BMJ Open, 2014, 4, e005186.	1.9	10
29	Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policies. International Journal of Urology, 2014, 21, 786-792.	1.0	11
30	Economic evaluations in bipolar disorder: a systematic review and critical appraisal. Bipolar Disorders, 2014, 16, 557-582.	1.9	20
31	Non-contact infrared thermometers for measuring temperature in children: primary care diagnostic technology update. British Journal of General Practice, 2014, 64, e681-e683.	1.4	21
32	Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25Âmg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care	1.6	29
33	alone: study protocol for a randomized controlled trial. Trials, 2014, 15, 160. Point-of-care testing for coeliac disease: primary care diagnostic technology update. British Journal of General Practice, 2013, 63, e426-e428.	1.4	6
34	The Oxford Renal (OxRen) cross-sectional study of chronic kidney disease in the UK. BMJ Open, 2013, 3, e004265.	1.9	7
35	Placebo Use in the United Kingdom: Results from a National Survey of Primary Care Practitioners. PLoS ONE, 2013, 8, e58247.	2.5	107
36	The D-Dimer test in combination with a decision rule for ruling out deep vein thrombosis in primary care: diagnostic technology update. British Journal of General Practice, 2012, 62, e393-e395.	1.4	5

JANE L WOLSTENHOLME

#	Article	IF	CITATIONS
37	Point-of-care INR coagulometers for self-management of oral anticoagulation: primary care diagnostic technology update. British Journal of General Practice, 2012, 62, e798-e800.	1.4	12
38	Point-of-care testing for the analysis of lipid panels: primary care diagnostic technology update. British Journal of General Practice, 2012, 62, e224-e226.	1.4	49
39	Spirometry in primary care for case finding and management of chronic obstructive pulmonary disease primary care diagnostic technology update. British Journal of General Practice, 2011, 61, 698-699.	1.4	4
40	Dermoscopy for the diagnosis of melanoma: primary care diagnostic technology update. British Journal of General Practice, 2011, 61, 416-417.	1.4	13
41	Primary care diagnostic technology update: point-of-care testing for glycosylated haemoglobin. British Journal of General Practice, 2011, 61, 139-140.	1.4	11
42	Point-of-care blood test for ketones in patients with diabetes: primary care diagnostic technology update. British Journal of General Practice, 2011, 61, 530-531.	1.4	13
43	Burden of disease and costs of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom. Cost Effectiveness and Resource Allocation, 2010, 8, 6.	1.5	100
44	Mapping the Modified Rankin Scale (mRS) Measurement into the Generic EuroQol (EQ-5D) Health Outcome. Medical Decision Making, 2010, 30, 341-354.	2.4	127
45	The costs and prognostic characteristics of ischaemic neurological deficit due to subarachnoid haemorrhage in the United Kingdom. Journal of Neurology, 2009, 256, 364-373.	3.6	20
46	From cost-effectiveness information to decision-making on liquid-based cytology: Mind the gap. Health Policy, 2009, 89, 193-200.	3.0	2
47	Treatment Pathways, Resource Use, and Costs of Endovascular Coiling Versus Surgical Clipping After aSAH. Stroke, 2008, 39, 111-119.	2.0	74
48	Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart, 2007, 93, 1081-1086.	2.9	53
49	Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies. BMJ: British Medical Journal, 2006, 332, 79-85.	2.3	54
50	Screening for cervical cancer in India: How much will it cost? A trial based analysis of the cost per case detected. International Journal of Cancer, 2005, 117, 981-987.	5.1	50
51	Willingness-to-Pay and Demand Curves: A Comparison of Results Obtained Using Different Elicitation Formats. International Journal of Health Care Finance and Economics, 2005, 5, 369-386.	1.2	21
52	Evidence of range bias in contingent valuation payment scales. Health Economics (United Kingdom), 2004, 13, 183-190.	1.7	46
53	Comparing willingness-to-pay: bidding game format versus open-ended and payment scale formats. Health Policy, 2004, 68, 289-298.	3.0	70
54	Missing presumed at random: cost-analysis of incomplete data. Health Economics (United Kingdom), 2003, 12, 377-392.	1.7	280

JANE L WOLSTENHOLME

#	Article	IF	CITATIONS
55	A comparison of two methods for eliciting contingent valuations of colorectal cancer screening. Journal of Health Economics, 2003, 22, 555-574.	2.7	61
56	Eliciting Willingness to Pay: Comparing Closed-Ended with Open-Ended and Payment Scale Formats. Medical Decision Making, 2003, 23, 150-159.	2.4	96
57	Estimating the relationship between disease progression and cost of care in dementia. British Journal of Psychiatry, 2002, 181, 36-42.	2.8	84
58	Collaborating with a primary care-based research network. Journal of Evaluation in Clinical Practice, 2001, 7, 339-342.	1.8	5
59	Mass population screening for colorectal cancer: factors influencing subjects' choice of screening test. Journal of Health Services Research and Policy, 2001, 6, 85-91.	1.7	29
60	A Review of Alternative Approaches to Healthcare Resource Allocation. Pharmacoeconomics, 2000, 18, 33-43.	3.3	23
61	Home-based versus hospital-based care for serious mental illness. British Journal of Psychiatry, 1998, 172, 506-512.	2.8	57
62	The Costs of Treating Breast Cancer in the United Kingdom: Implications for Screening. International Journal of Technology Assessment in Health Care, 1998, 14, 277-289.	0.5	32